Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 4 | 2026 | 312 | 1.510 |
Why?
|
| Burkitt Lymphoma | 3 | 2024 | 134 | 0.960 |
Why?
|
| Malawi | 14 | 2026 | 339 | 0.930 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 236 | 0.930 |
Why?
|
| Methotrexate | 2 | 2025 | 342 | 0.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1356 | 0.910 |
Why?
|
| Capacity Building | 1 | 2025 | 26 | 0.900 |
Why?
|
| Sarcoma, Kaposi | 5 | 2025 | 130 | 0.860 |
Why?
|
| Hematologic Diseases | 1 | 2025 | 82 | 0.840 |
Why?
|
| Malnutrition | 2 | 2025 | 156 | 0.830 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 187 | 0.800 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 149 | 0.790 |
Why?
|
| Mucositis | 1 | 2022 | 19 | 0.760 |
Why?
|
| Neoplasms | 7 | 2026 | 2969 | 0.690 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 163 | 0.670 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 295 | 0.570 |
Why?
|
| Child | 26 | 2026 | 26299 | 0.520 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 269 | 0.500 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 165 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2017 | 358 | 0.450 |
Why?
|
| Africa South of the Sahara | 3 | 2025 | 120 | 0.430 |
Why?
|
| HIV Infections | 5 | 2026 | 2037 | 0.360 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 47 | 0.360 |
Why?
|
| Child, Preschool | 12 | 2026 | 15057 | 0.330 |
Why?
|
| Vincristine | 2 | 2020 | 194 | 0.290 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17667 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 442 | 0.260 |
Why?
|
| Adolescent | 12 | 2026 | 20982 | 0.260 |
Why?
|
| Humans | 27 | 2026 | 131679 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5297 | 0.250 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 19 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.230 |
Why?
|
| Legal Guardians | 1 | 2024 | 12 | 0.220 |
Why?
|
| Male | 16 | 2026 | 65266 | 0.220 |
Why?
|
| Anti-Retroviral Agents | 1 | 2026 | 153 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2026 | 221 | 0.210 |
Why?
|
| Female | 16 | 2026 | 71185 | 0.210 |
Why?
|
| Developing Countries | 1 | 2025 | 304 | 0.190 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 15 | 0.190 |
Why?
|
| Anti-HIV Agents | 1 | 2026 | 359 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2025 | 285 | 0.180 |
Why?
|
| Malaria, Falciparum | 1 | 2022 | 67 | 0.180 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 17 | 0.180 |
Why?
|
| Quality of Life | 2 | 2022 | 2118 | 0.180 |
Why?
|
| Malaria | 1 | 2022 | 99 | 0.180 |
Why?
|
| Wilms Tumor | 1 | 2023 | 120 | 0.180 |
Why?
|
| Hematology | 1 | 2022 | 42 | 0.180 |
Why?
|
| Infant | 7 | 2026 | 13306 | 0.160 |
Why?
|
| Creatinine | 1 | 2022 | 402 | 0.160 |
Why?
|
| Terminal Care | 1 | 2022 | 114 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2022 | 302 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 218 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 578 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 505 | 0.150 |
Why?
|
| Anemia | 1 | 2023 | 355 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1277 | 0.140 |
Why?
|
| Vinblastine | 1 | 2018 | 55 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1306 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1947 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 454 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 69 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 325 | 0.140 |
Why?
|
| Etoposide | 1 | 2018 | 117 | 0.140 |
Why?
|
| Bleomycin | 1 | 2018 | 111 | 0.140 |
Why?
|
| Dacarbazine | 1 | 2018 | 93 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 904 | 0.140 |
Why?
|
| Lymphoma | 1 | 2021 | 330 | 0.140 |
Why?
|
| Podophyllotoxin | 1 | 2017 | 6 | 0.130 |
Why?
|
| Carmustine | 1 | 2017 | 22 | 0.130 |
Why?
|
| Melphalan | 1 | 2017 | 44 | 0.130 |
Why?
|
| Autografts | 1 | 2017 | 29 | 0.130 |
Why?
|
| Survival Rate | 2 | 2025 | 2151 | 0.130 |
Why?
|
| Cytarabine | 1 | 2017 | 101 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2018 | 301 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Prognosis | 3 | 2025 | 4952 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2025 | 6494 | 0.120 |
Why?
|
| Pediatrics | 1 | 2025 | 1231 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 910 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1348 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1164 | 0.090 |
Why?
|
| Adult | 4 | 2024 | 31719 | 0.090 |
Why?
|
| Risk Factors | 2 | 2026 | 10959 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2694 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 99 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3834 | 0.050 |
Why?
|
| Tanzania | 1 | 2023 | 68 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 175 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1483 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 708 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 597 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 141 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 237 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8589 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 32 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 439 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 684 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 445 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1260 | 0.040 |
Why?
|
| Apoptosis | 1 | 2026 | 1861 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 221 | 0.040 |
Why?
|
| Transcriptome | 1 | 2026 | 1163 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1833 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1322 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 697 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 646 | 0.040 |
Why?
|
| Incidence | 1 | 2026 | 3347 | 0.030 |
Why?
|
| Palliative Care | 1 | 2022 | 444 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2019 | 419 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 837 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1099 | 0.030 |
Why?
|
| United States | 1 | 2023 | 11804 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 10104 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 28888 | 0.010 |
Why?
|